The FGFR-inhibitor derazantinib (DZB) is active in PDX-models of GI-cancer with specific aberrations in FGFR.

Paul M.J. McSheehy,Felix Bachmann,Nicole Forster-Gross,Mahmoud El-Shemerly,Mila Roceri,Laurenz Kellenberger,Heidi Lane

The FGFR-inhibitor derazantinib (DZB) is active in PDX-models of GI-cancer with specific aberrations in FGFR.

2020

Paul M.J. McSheehy
Felix Bachmann
Nicole Forster-Gross
Mahmoud El-Shemerly
Mila Roceri
Laurenz Kellenberger
Heidi Lane

421Background: DZB is an oral small-molecule Fibroblast Growth Factor Receptor 1/2/3 inhibitor (FGFRi) with clinical activity in FGFR2-fusion-positive cholangiocarcinoma. DZB was screened for activ...

Keywords:

Cancer
Cancer research
Medicine
Fibroblast growth factor receptor
Pathology
Fibroblast growth factor receptor 1
gi cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations